Generic Name and Formulations:
Amphotericin B lipid complex 5mg/mL; susp for IV infusion after dilution; preservative-free.
Sigma-Tau Pharmaceuticals, Inc.
Indications for ABELCET:
Invasive fungal infections in patients who are refractory to, or intolerant of, conventional amphotericin B therapy.
Adults and Children:
5mg/kg daily as a single IV infusion, at a rate of 2.5mg/kg per hour. Renal impairment: reduce dose.
Be fully familiar with the use of this product. Administer under close supervision; cardiopulmonary resuscitation facilities should be available. Monitor CBC, serum creatinine, liver function, serum electrolytes (esp. magnesium and potassium). Pregnancy (Cat.B). Nursing mothers: not recommended.
Monitor other drugs; see literature. Caution with antineoplastics, corticosteroids, ACTH, cyclosporine, digitalis glycosides, flucytosine, imidazoles, nephrotoxic drugs, skeletal muscle relaxants, zidovudine. Concurrent leukocyte transfusion: not recommended.
Infusion reactions (1–2 hrs post-infusion, e.g., transient chills/fever, rarely: bronchospasm, hypotension, arrhythmias, shock), nephrotoxicity, hepatotoxicity, anaphylaxis, respiratory/cardiac/neurological disorders, malaise, tinnitus, visual impairment, hearing loss, diarrhea; others: see literature.
Single-use vials (50mg, 100mg)—1 (w. filter needle)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|